-+ 0.00%
-+ 0.00%
-+ 0.00%

enprex Announces Strategic CDMO Collaboration For Diabetes Gene Therapy Using Non-Viral Delivery System

Benzinga·02/19/2025 13:16:46
Listen to the news

Researching Novel Diabetes Gene Therapy Using Potentially Re-Dosable Non-Viral Delivery System

Strategic Collaboration with CDMO Partner Positions Genprex as a Thought-Leader in Diabetes Market

AUSTIN, Texas, Feb. 19, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the advancement of its diabetes program through a strategic collaboration with a contract development and manufacturing organization (CDMO) to research an alternative second generation approach using a non-viral lipid nanoparticle delivery of the Company's diabetes gene therapy drug candidate.